Effect of Bevacizumab on Pterygium: A Case Series Study
Journal of Ophthalmic and Optometric Sciences,
Vol. 8 No. 4 (2024),
22 September 2024
,
Page 1-6
https://doi.org/10.22037/joos.v8i4.48650
Abstract
Purpose: to study evaluate the effectiveness of a single subconjunctival injection of bevacizumab (Avastin), an anti-vascular endothelial growth factor (VEGF) agent, in reducing pterygium size and vascularization among patients with primary pterygium.
Patients and Methods: Seventeen patients with primary pterygium were enrolled in this case series study. Each patient received a single subconjunctival injection of 1.25 mg bevacizumab. Follow-up evaluations were conducted at one week, one month, and three months post-injection. The primary outcomes included changes in symptoms such as itching, redness, tearing, and burning, as well as pterygium size and vascularization. Statistical analysis was performed using Repeated Measures ANOVA and Paired T-tests.
Results: Itching significantly decreased within the first week and remained stable at three months. Pterygium vascularization was also reduced. However, changes in pterygium size, astigmatism, and refraction were not statistically significant. No serious adverse effects were reported.
Conclusion: A single dose injection of subconjunctival bevacizumab significantly reduces vascularization and itching in pterygium. However, its impact on pterygium size remains unclear. While surgical excision remains the gold standard, subconjunctival bevacizumab offers an alternative treatment approach for patients seeking a minimally invasive alternative. Further studies are needed to determine optimal dosing strategies and long-term effects.
- Pterygium
- Bevacizumab
- Anti-VEGF Therapy
- Ocular Angiogenesis
How to Cite
References
- Shahraki T, Arabi A, Feizi S. Pterygium: an update on pathophysiology, clinical features, and management. Ther Adv Ophthalmol. 2021;13:25158414211020152.
- Safarzadeh M, Heidari S, Azizzadeh P, Sheibani K, Nassiri N, Heidari L, et al. Comparative Assessment of Tear Function Tests, Tear Osmolarity, and Conjunctival Impression Cytology between Patients with Pterygium and Healthy Eyes. J Ophthalmic Vis Res. 2019;14(1):11-17.
- Böhm EW, Buonfiglio F, Voigt AM, Bachmann P, Safi T, Pfeiffer N, Gericke A. Oxidative stress in the eye and its role in the pathophysiology of ocular diseases. Redox Biol. 2023;68:102967.
- Noureddin GS, Yeung SN. The use of dry amniotic membrane in pterygium surgery. Clin Ophthalmol. 2016;10:705-12.
- Mohammad-Salih PA, Sharif AF. Analysis of pterygium size and induced corneal astigmatism. Cornea. 2008;27(4):434-8.
- Xu Y, Qiao C, He S, Lu C, Dong S, Wu X, et al. Identification of Functional Genes in Pterygium Based on Bioinformatics Analysis. Biomed Res Int. 2020;2020:2383516.
- Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157(1):135-44.
- Meng Q, Qin Y, Deshpande M, Kashiwabuchi F, Rodrigues M, Lu Q, Ren H, et al. Hypoxia-Inducible Factor-Dependent Expression of Angiopoietin-Like 4 by Conjunctival Epithelial Cells Promotes the Angiogenic Phenotype of Pterygia. Invest Ophthalmol Vis Sci. 2017;58(11):4514-23.
- Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328-35.
- Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol. 2007;55(6):417-20.
- Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007;69(4):925-7.
- Mak RK, Chan TC, Marcet MM, Choy BN, Shum JW, Shih KC, et al. Use of anti-vascular endothelial growth factor in the management of pterygium. Acta Ophthalmol. 2017;95(1):20-27.
- Drzyzga Ł, Śpiewak D, Dorecka M, Wyględowska-Promieńska D. Available Therapeutic Options for Corneal Neovascularization: A Review. Int J Mol Sci. 2024;25(10):5479.
- Sayadi J, Gouider D, Henchiri M, Choura R, Boujelbene N, Abbes I,et al. Preoperative Intralesional Bevacizumab Injection in Primary Pterygium in Tunisian Patients: A Randomized Controlled Prospective Study. J Curr Ophthalmol. 2022;34(3):297-304.
- Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28(4):468-70.
- Stival LR, Lago AM, Figueiredo MN, Bittar RH, Machado ML, Nassaralla Junior JJ. Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium. Arq Bras Oftalmol. 2014;77(1):4-7.
- Ghoz N, Britton J, Ross AR, Mohammed I, Hogan E, Said DG, Dua HS. Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin). Eye (Lond). 2019;33(11):1776-1783.
- Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57(5):415-29.
- Hu Q, Qiao Y, Nie X, Cheng X, Ma Y. Bevacizumab in the treatment of pterygium: a meta-analysis. Cornea. 2014;33(2):154-60.
- Zhang B, Dong X, Sun Y. Efficacy and safety of anti-vascular endothelial growth factor agents in the treatment of primary pterygium. Front Med (Lausanne). 2023;10:1166957.
- Fallah Tafti MR, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea. 2011;30(2):127-9.
- Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea. 2012;31(2):155-61.
- Nuzzi R, Tridico F. Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence. J Ophthalmol. 2017;2017:6824670.
- Sun Y, Zhang B, Jia X, Ling S, Deng J. Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials. J Ophthalmol. 2018;2018:4598173.
- Ghiasian L, Samavat B, Hadi Y, Arbab M, Abolfathzadeh N. Recurrent Pterygium: A Review. J Curr Ophthalmol. 2022;33(4):367-78.
- Khoshniat H, Hosseini HR, Nejabat M, Fatehi K, Mosallaei M. Local injection of bevacizumab as an alternative method for management of recurrent pterygium. Iranian Red Crescent Medical Journal. 2009;11(3):306-11.
- Shahraki T, Arabi A, Feizi S. Pterygium: an update on pathophysiology, clinical features, and management. Ther Adv Ophthalmol. 2021;13:25158414211020152.
- Abstract Viewed: 58 times
- pdf Downloaded: 67 times
